-Great management that is executing. Startup of the year in 2018. They are laser focused.
-They are signing the biggest deals. $35M, with $7 upfront, $12M additional option.
-They are signing international deals. Auscann, with Canopy as an investor.
-They'll start exporting from Canada, later this year. -They could announce another facility location in Canada.
-They'll start producing and exporting from the new Australian facility later this year! Asian-Pacific markets. -They could announce a new international facility, I'm thinking Germany.
-Pharmaceutical background and focus. Extraction focus on exact cannabinoids at pharmaceutical grade and purity. Look for a big pharma deal eventually.
-Consumer packaged good deals very likely at some point. I don't think they'll leave it strictly to the LPs to make these deals.
-Loose guidance through a media article for $85M over next 15 months.
-Lower risk of not relying on the growth of cannabis and focused on higher margin extractions.
-Relationships with top LPs: Canopy, Cronos, Supreme, and largest deal was undisclosed LP.
I've run a lot of forecast numbers, and they all point to a stock price that could/should see $10+.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.